In 2023, Malaysia's current health expenditure stood at $1.26 thousand US dollars PPP per capita. Forecasted data indicates a consistent upward trend: $1.3 in 2024, $1.34 in 2025, $1.38 in 2026, $1.42 in 2027, and $1.47 in 2028.
Year-on-year variations:
- 2023-2024: 3.17%
- 2024-2025: 3.08%
- 2025-2026: 2.99%
- 2026-2027: 2.90%
- 2027-2028: 3.52%
The compounded annual growth rate (CAGR) over the last five years is approximately 3.13%. This indicates a stable and continuous increase in health spending per capita.
Future trends to watch for:
- Policy changes impacting healthcare funding and expenditures.
- Economic factors influencing the overall spending capacity.
- Technological advancements expanding healthcare services and efficiencies.
Latest reports
US Autoimmune Disease Market Report- Q1 2025
The US autoimmune disease market in Q1 2025 is experiencing significant shifts driven by advancements in biosimilars, biologics, and innovative therapies. The focus...
China Autoimmune Disease Market Report- Q1 2025
The autoimmune disease market in China has experienced substantial growth in the first quarter of 2025, driven by significant advancements in biopharmaceutical developments,...
Japan Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 witnessed significant developments in the autoimmune disease market in Japan, driven by technological advancements and strategic collaborations that...
Germany Autoimmune Disease Market Report- Q4 2024
The fourth quarter of 2024 marked a significant period for the autoimmune disease market in Germany, driven by advancements in treatment options and...
UK Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 has seen significant developments in the Autoimmune Disease UK market, driven by advancements in personalized medicine, increasing prevalence...
South Korea Autoimmune Disease Market Report- Q1 2025
The first quarter of 2025 marks a pivotal period for the Autoimmune Disease Market in South Korea, characterized by significant economic, technological, and...